Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric pharmacokinetics and pharmacodynamics of guanabenz for the treatment of vanishing white matter.

Scientific reports·2026
Same author

Expanding the Clinicoradiologic Phenotype of the <i>CTSA</i>-Associated Small Vessel Disease CARASAL: A Comparison With CADASIL.

Neurology. Genetics·2026
Same author

A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema.

Annals of clinical and translational neurology·2026
Same author

Hypomyelination of Early Myelinating Brain Structures.

Neuropediatrics·2026
Same author

Longitudinal MRI-based changes in intracranial volume and skull thickness observed in both metachromatic leukodystrophy and multiple sclerosis.

NeuroImage. Clinical·2026
Same author

Astrocyte-specific deletion of LRRC8A causes neurological dysfunction but not chronic white matter edema.

Neurobiology of disease·2026

Related Experiment Video

Updated: Jun 18, 2026

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model
05:12

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

Published on: September 4, 2017

AGC1 deficiency and cerebral hypomyelination

Nicole I Wolf, Marjo S van der Knaap

    The New England Journal of Medicine
    |November 13, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
    11:47

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

    Published on: January 22, 2017

    An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
    07:45

    An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

    Published on: October 21, 2014

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model
    05:12

    Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model

    Published on: September 4, 2017

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
    11:47

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

    Published on: January 22, 2017

    An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
    07:45

    An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

    Published on: October 21, 2014